Bounded definition
A process that administers editor components directly so that delivery, editing, and biological response occur inside the participant or organism.
What the cited work establishes
The phase 1 report describes systemic lipid-nanoparticle delivery of CRISPR components and early dose-cohort biomarker and safety observations in adults with transthyretin amyloidosis.
The constructs, biological systems, protocols, assays, datasets, and comparisons reported in CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis.
Claims: urn:maha:claim:in-vivo-genome-editing-workflow
What remains a separate question
Early dose-cohort observations do not establish long-term benefit, rare-event safety, repeatability, or transfer to another organ and target.
Early biomarker and safety observations do not establish long-term clinical benefit, rare-event safety, or transfer to other tissues and targets.
Connected domain graph
Typed dependencies preserve publication state.
Only independently canonical records receive public links and relation statements. Draft graph topology remains private.
Genome-editor delivery systems
inbound connection · method
In-vivo editing depends on tissue exposure produced by a delivery system.
Genome-editor delivery systems
outbound connection · method
The in-vivo workflow depends on tissue-specific delivery and exposure.
In-vitro versus in-vivo evidence
outbound connection · comparison
In-vivo observations are a distinct evidence state from biochemical and cell-culture experiments.
In-vitro versus in-vivo evidence
inbound connection · comparison
The in-vivo workflow supplies one human intervention evidence state.
Claim ledger
Every proposition keeps its own evidence state.
The cited phase 1 report describes systemic administration, dose cohorts, biomarker response, and early safety observations for a liver-targeted CRISPR intervention.
- Scope
- The constructs, biological systems, protocols, assays, datasets, and comparisons reported in CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis.
- Boundary
- Early dose-cohort observations do not establish long-term benefit, rare-event safety, repeatability, or transfer to another organ and target.
- Uncertainty
- There is no universal effect estimate for this method; numerical results remain attached to the source experiment, biological system, assay, and analysis choices.
- Replication
- This candidate records one bounded source package. Independent replications and contradictory results must be compiled separately before evidence maturity is upgraded.
Primary sources
Citation, locator, rights, and boundary travel together.
Source 1 · The New England Journal of Medicine
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Julian D. Gillmore, Ed Gane, Julian Taubel, Jingzhu Kao, et al.
- Exact locator
- Abstract; Methods; Results; Figures 1–3; supplementary protocol and statistical analysis.
- Establishes
- The phase 1 report describes systemic lipid-nanoparticle delivery of CRISPR components and early dose-cohort biomarker and safety observations in adults with transthyretin amyloidosis.
- Boundary
- Early biomarker and safety observations do not establish long-term clinical benefit, rare-event safety, or transfer to other tissues and targets.
- Rights basis
- citation with paraphrase · Maha paraphrases the source-level result and links to the version of record; no article passage is reproduced.
- Declared interests
- The study was funded by Intellia Therapeutics and Regeneron Pharmaceuticals; author relationships are disclosed.